SAB2702342

Monoclonal Anti-HIF2 alpha antibody produced in mouse

Name: Monoclonal Anti-HIF2 alpha antibody produced in mouse
Brand: SIGMA
Price: 519 USD

clone GT125, affinity isolated antibody

Synonym(s):

ECYT4, HIF2A, HLF, MOP2

Slide 1 of 5

Select a Size

100 μL

$519.00

Usually ships in 1 week. (Orders outside of US and Europe, please allow an additional 1-2 weeks for delivery)

A recombinant, preservative-free antibody is available for your target. Try ZRB2228

About This Item

NACRES:

NA.41

UNSPSC Code:

12352203

Conjugate:

unconjugated

Clone:

GT125, monoclonal

Application:

IF, IP, WB

Citations:

Key Documents

View All Documentation

biological source

mouse

conjugate

unconjugated

antibody form

affinity isolated antibody

antibody product type

primary antibodies

clone

GT125, monoclonal

form

buffered aqueous solution

mol wt

96kDa

species reactivity

rat, mouse, human

concentration

3mg/mL

technique(s)

immunoprecipitation (IP): suitable, indirect immunofluorescence: suitable, western blot: 500-3000

isotype

IgG1

UniProt accession no.

Q99814

shipped in

wet ice

storage temp.

−20°C

target post-translational modification

unmodified

Quality Level

100

Gene Information

human ... EPAS1(2034)

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item	H6536	H6411	SAB1408977
Sigma-Aldrich SAB2702342 Monoclonal Anti-HIF2 alpha antibody produced in mouse	Sigma-Aldrich H6536 Monoclonal Anti-HIF-1α antibody produced in mouse	Sigma-Aldrich H6411 Monoclonal Anti-HIF-1α antibody produced in mouse	Sigma-Aldrich SAB1408977 Anti-EPAS1 antibody produced in mouse
species reactivity rat, mouse, human	species reactivity rat, sheep, ferret, human, mouse	species reactivity human	species reactivity human
antibody form affinity isolated antibody	antibody form purified immunoglobulin	antibody form purified immunoglobulin	antibody form purified immunoglobulin
conjugate unconjugated	conjugate unconjugated	conjugate unconjugated	conjugate unconjugated
Gene Information human ... EPAS1(2034)	Gene Information human ... HIF1A(3091) mouse ... Hif1a(15251) rat ... Hif1a(29560)	Gene Information human ... HIF1A(3091)	Gene Information human ... EPAS1(2034)
clone GT125, monoclonal	clone H1α67, monoclonal	clone OZ12, monoclonal	clone polyclonal
biological source mouse	biological source mouse	biological source mouse	biological source mouse

General description

Hypoxia-inducible factor 2-α (HIF2) also known as endothelial PAS domain protein 1 (EPAS1) belongs to the helix-loop-helix/ Per-Arnt-Sim (PAS) transcription factor family. The HIF2 gene is mapped to human chromosome 2p21. HIF2 is expressed in endothelial cells, hepatocytes, lung, cardiomyocytes, and renal fibroblasts.

Immunogen

Recombinant protein encompassing a sequence within the center region of human HIF2 alpha.

Application

Suggested starting dilutions are as follows: ICC/IF: 1:100-1:1000, IP: 1:100-1:700, WB: 1:500-1:3000. Not yet tested in other applications. Optimal working dilutions should be determined experimentally by the end user.

Biochem/physiol Actions

Hypoxia-inducible factor 2-α (HIF2) regulates oxygen physiology and modulates the hypoxic response. It favors chondrosarcoma progression. Mutations in the HIF2 Phe-540 residue abolishes its interaction with von hippel lindau (VHL) and prolyl hydroxylase domain-2 (PHD2). HIF2 regulates erythropoietin synthesis and is implicated in the pathophysiology of excessive erythrocytosis (EE). Mutations in the HIF2 gene impair response to the changes in oxygen tension. A gain-of-function mutation of HIF2 results in Zhuang syndrome.

Features and Benefits

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

Physical form

Phosphate-buffered saline, no preservative added.

Other Notes

Purification: Affinity purified by Protein G

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?

Try our Product Selector Tool.

Storage Class

12 - Non Combustible Liquids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

42023

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Two new mutations in the HIF2A gene associated with erythrocytosis.

Melanie J Percy et al.

American journal of hematology, 87(4), 439-442 (2012-03-01)

Vascular Changes in the Retina and Choroid of Patients With EPAS1 Gain-of-Function Mutation Syndrome.

Pauline M Dmitriev et al.

JAMA ophthalmology, 138(2), 148-155 (2019-12-27)

Patients with the EPAS1 gain-of-function mutation syndrome (or Pacak-Zhuang syndrome) present with multiple paragangliomas or pheochromocytomas, duodenal somatostatinoma, polycythemia, headaches, and sometimes diminished visual acuity at an early age. The characteristic phenotype and known genetic cause of the syndrome provide

The A Allele at rs13419896 of EPAS1 Is Associated with Enhanced Expression and Poor Prognosis for Non-Small Cell Lung Cancer.

Andika C Putra et al.

PloS one, 10(8), e0134496-e0134496 (2015-08-12)

Hypoxia-inducible factor-2α (HIF-2α, or EPAS1) is important for cancer progression, and is a putative biomarker for poor prognosis for non-small cell lung cancer (NSCLC). However, molecular mechanisms underlying the EPAS1 overexpression are not still fully understood. We explored a role

A system-level approach identifies HIF-2α as a critical regulator of chondrosarcoma progression.

Hyeonkyeong Kim et al.

Nature communications, 11(1), 5023-5023 (2020-10-08)

Chondrosarcomas, malignant cartilaginous neoplasms, are capable of transitioning to highly aggressive, metastatic, and treatment-refractory states, resulting in significant patient mortality. Here, we aim to uncover the transcriptional program directing such tumor progression in chondrosarcomas. We conduct weighted correlation network analysis

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service